Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.

导出原文传递

翻译打印收藏纠错

作者： Stephanie,Lheureux ^[1] ; Zhongwu,Lai ^[2] ; Brian A,Dougherty ^[2] ; Sarah,Runswick ^[3] ; Darren R,Hodgson ^[3] ; Kirsten M,Timms ^[4] ; Jerry S,Lanchbury ^[4] ; Stan,Kaye ^[5] ; Charlie,Gourley ^[6] ; David,Bowtell ^[7] ; Elise C,Kohn ^[8] ; Claire,Scott ^[9] ; Ursula,Matulonis ^[10] ; Tony,Panzarella ^[11] ; Katherine,Karakasis ^[1] ; Julia V,Burnier ^[1] ; C Blake,Gilks ^[12] ; Mark J,O'Connor ^[13] ; Jane D,Robertson ^[3] ; Jonathan,Ledermann ^[14] ; J Carl,Barrett ^[2] ; Tony W,Ho ^[15] ; Amit M,Oza ^[16]

作者单位： Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada. ^[1] AstraZeneca, Waltham, Massachusetts. ^[2] AstraZeneca, Macclesfield, United Kingdom. ^[3] Myriad Genetics, Inc., Salt Lake City, Utah. ^[4] The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom. ^[5] University of Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom. ^[6] Peter MacCallum Cancer Centre, Melbourne, and Garvan Institute for Medical Research, Sydney, Australia. ^[7] Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland. ^[8] Royal Melbourne Hospital, Melbourne, Australia. ^[9] Dana-Farber Cancer Institute, Boston, Massachusetts. ^[10] Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Canada. ^[11] Department of Pathology, Vancouver General Hospital, Vancouver, Canada. ^[12] AstraZeneca, Cambridge, United Kingdom. ^[13] Cancer Institute, University College London, and University College London Hospitals, London, United Kingdom. ^[14] AstraZeneca, Gaithersburg, Maryland. ^[15] Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada. amit.oza@uhn.on.ca. ^[16]